AndhraNews.net
Home » Business News » 2013 » November » November 18, 2013

Glycotope's Fully Human and Glycooptimized Recombinant FSH-GEX(TM) Showed Superior Activity and Excellent Tolerability in a Phase II Clinical Trial for In Vitro Fertilisation


November 18, 2013 - London

Glycotope GmbH /Glycotope's Fully Human and Glycooptimized Recombinant FSH-GEX(TM) Showed Superior Activity and Excellent Tolerability in a Phase II Clinical Trial for In Vitro Fertilisation . Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Berlin, Germany, November 18th, 2013 - Glycotope GmbH, a global leader in developing therapeutic antibodies targeting glycosylated epitopes on cancer cells and optimizing the sugar chains (glycosylation) of biopharmaceuticals, today announced results from the Phase II clinical trial with FSH-GEXTM for Assisted Reproductive Technologies. Results showed that FSH-GEXTM has superior activity and excellent tolerability when compared to the standard treatment Gonal-f®. FSH-GEXTM is the first fully human glycosylated FSH (follicle-stimulating hormone), recombinantly expressed in human cells and glycooptimized to mimic endogenous human FSH.

The Phase II, multicenter, multinational, randomized clinical trial investigated the efficacy and safety of varying doses and schedules of FSH-GEXTM in comparison with daily 150 IU Gonal-f® in 247 women undergoing artificial insemination by intracytoplasmic sperm injection (ICSI) treatment in an agonist protocol. FSH-GEXTM was tested in five dose cohorts, 52.5 IU, 75 IU, 112.5 IU and 150 IU daily doses, and 150 IU given every second day, compared to the standard daily dose of 150 IU Gonal-f®.

The data show that FSH-GEXTM, even at half the biologic dose (75 IU FSH-GEXTM), is at least as active as Gonal-f (150 IU) in all FSH mediated parameters and endpoints. These data confirm the superior preclinical, Phase Ia and Ib data regarding biological activity and clinical efficacy.

For example, the FSH-GEXTM dose of 112.5 IU, showed superiority over all FSH mediated aspects and endpoints compared to a 33% higher Gonal-f® standard dose including follicular response, as well as high biochemical (57.5%) and ongoing (50.0%) pregnancy rates. Particularly important for future clinical use are the statistically significantly improved numbers of retrieved oocyte complexes (+29.5%) and high quality metaphase II oocytes (+24.5%), as well as a strong trend for more pronuclear (PN) 2 oocytes (+21%) which could be observed in this dose regimen.

Furthermore, the results at a dose regimen with 150 IU FSH-GEXTM applied every second day and 75 IU FSH-GEXTM administered on a daily basis were fully comparable, allowing for a flexible or alternative dosing regimen with the same product.

The treatment with FSH-GEXTM was safe and very well tolerated, while Gonal-f® showed the highest rate of OHSS (Ovarian hyperstimulation syndrome) during the trial. No inductions of anti drug antibody (ADA) responses were observed in FSHGEXTM patients.

"FSH-GEXTM is the first of our glycooptimized, fully human non-antibody molecules validating our unique GlycoExpressTM platform and proving our commitment to delivering better, clinically superior therapies combined with commercially attractive terms," said Dr. Steffen Goletz, CEO, CSO and Founder of Glycotope. "The superior activity and improved properties of FSH-GEXTM, which allows for lower FSH doses and the significantly improved numbers of high quality mature oocytes that can be achieved for in vitro fertilisation, are seen as a key driver for best clinical performances. These results strongly indicate not only a high relevance of FSHGEXTM in the tested broad patient cohort but also yield hope for women whose ovaries are particularly hard to stimulate and who are experiencing major difficulties in becoming pregnant. We are excited about these results and anticipate starting Phase III clinical trials in 2014," he added.

About FSH and In Vitro Fertilisation

The follicle-stimulating hormone (FSH) is responsible for follicle maturation. Its main clinical use is administration during the onset of in vitro fertilization procedures t induce maturation of multiple oocytes for retrieval.

Currently, approved preparations of FSH originate from either human urine or recombinant sources from non-human cells. While urinary versions of FSH carry a heterogeneous but human glycosylation, the generally better biological safety of recombinant products makes them the product of choice for most patients, despite a non-human glycosylation profile and higher product costs associated with the treatment.

Glycotope's glycooptimized and fully human version of FSH, FSH-GEXTM, combines the advantages of both product types into one single product and adds efficacy advantages. The aim of the program was to generate a BioSuperior molecule mimicking the FSH of a healthy woman. Using GlycoExpressTM, which allows for fully human glycosylation and optimization of this process, FSH-GEXTM showed an improved activity in human in vitro assays as well as in the first trials and superior production yields and reproducibility of quality by production in GlycoExpressTM. It thereby provides the safety advantages of a recombinant protein with the advantages of a fully human glycosylation and an optimized glycosylation.

About Glycotope

Glycotope, founded 2001 in Berlin, focuses on the development of innovative antibodies for the treatment of various cancer types. These GlycoBodiesTM target glycostructures or carbohydrate-peptide mixed epitopes on cell surfaces. In addition, Glycotope develops so-called BioSuperiors, antibody and non-antibody recombinant biopharmaceuticals with optimized and fully human sugar structures for clinical superiority. Key to the glycooptimization technology is a toolbox of glycoengineered proprietary human cell lines that allow the glycooptimization of proteins in respect to a whole series of different determining sugars and is based on fully human glycosylation. GlycoExpressTM allows the selection of the most appropriate and best suitable human glycoform of a product and a high yield production superior in reproducibility, quality and yield. Glycooptimization via GlycoExpressTM provides improved efficacy, bioavailability, immunogenicity and broadens the potential patient populations and indications, as well as providing a much improved cost-effectiveness. Glycotope has currently four products in clinical development from late stage Phase I to late stage Phase II. The Company's additional pipeline includes preclinical non-antibody and antibody biopharmaceuticals for various indications.

Together with its subsidiary, Glycotope Biotechnology in Heidelberg, Glycotope has evolved into a leading fully integrated glycobiology company, covering the entire workflow from discovery, molecule optimization, clone and process development, preclinical and clinical drug development to GMP production. With more than 160 employees and a strong, broad IP-platform, Glycotope today is one of the largest biotechnology companies in Germany.

Contact:
Glycotope GmbH
Dr. Franzpeter Bracht, CFO & CBO
Robert-Roessle-Str. 10, D-13125 Berlin, Germany
Phone: +49-(0)30 94 89-2600
Fax: +49-(0)30 94 89-2609
Email: Franzpeter.Bracht@glycotope.com
Website: www.glycotope.com

Press Release PDF



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Glycotope GmbH via Thomson Reuters ONE

HUG#1743809

GlobeNewswire

Comment on this story

Share